- Record: found
- Abstract: found
- Article: not found
Early intervention with phosphodiesterase-5 inhibitors after prostate brachytherapy improves subsequent erectile function.
Geetu Pahlajani
1 ,
Rupesh Raina ,
J Stephen Jones ,
Michael Burdick ,
Marwan Ali ,
Jianbo Li ,
Arul Mahadevan ,
Jay Ciezki ,
Craig Zippe
Nov 2010
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
To examine the early use of phosphodiesterase-5 inhibitor (PDE-5i; sildenafil citrate) in preventing subsequent erectile dysfunction (ED) after (monotherapy) prostate brachytherapy (PB, an accepted option for Gleason 6 or low-volume Gleason 7 prostate cancer), as PB is currently being offered more frequently in younger patients, and ED can be a side-effect often within the first 12 months after treatment.